ICON plc (ICLR)
| Market Cap | 9.54B |
| Revenue (ttm) | 2.80B |
| Net Income (ttm) | 332.33M |
| Shares Out | 52.86M |
| EPS (ttm) | 6.15 |
| PE Ratio | 29.38 |
| Forward PE | 21.88 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $180.68 |
| Previous Close | $184.44 |
| Change ($) | -3.76 |
| Change (%) | -2.04% |
| Day's Open | 185.00 |
| Day's Range | 179.54 - 186.62 |
| Day's Volume | 1,464,984 |
| 52-Week Range | 104.28 - 223.62 |
NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of PR...
Icon PLC (ICLR) delivered earnings and revenue surprises of 3.83% and 1.57%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2020 Results
DUBLIN--(BUSINESS WIRE)--ICON to acquire PRA Health Sciences, creating a world leader in Healthcare Intelligence and Clinical Research
Icon (NASDAQ:ICLR) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.
Icon PLC (ICLR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announc...
Icon PLC (ICLR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DUBLIN, Ireland--(BUSINESS WIRE)--ICON plc to Present at the 39th Annual JP Morgan Healthcare Conference
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ:ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical de...
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference and Evercore ISI HealthCONx Conference
ICON Public Limited Company (ICLR) CEO Steve Cutler on Q3 2020 Results - Earnings Call Transcript
Icon PLC (ICLR) delivered earnings and revenue surprises of 10.97% and 5.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Icon (NASDAQ:ICLR) moved lower by 0.6% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 1.15% year over year to $1.72, wh...
DUBLIN, Ireland--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical ...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device in...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device in...
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at Wells Fargo 2020 Virtual Global Healthcare Conference and Baird 2020 Global Healthcare Conference
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a leading global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industrie...
ICON's (ICLR) CEO Steven Cutler on Q2 2020 Results - Earnings Call Transcript
Icon PLC (ICLR) delivered earnings and revenue surprises of 9.09% and 4.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Icon (NASDAQ:ICLR) were unchanged after the company reported Q2 results.
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wayfair stock benefited from the novel coronavirus and is up big year to date. It’s time to consider other stocks.
ICON Public Limited Company (ICLR) CEO Dr. Steven Cutler on Q1 2020 Results - Earnings Call Transcript
Icon PLC (ICLR) delivered earnings and revenue surprises of -1.16% and 0.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
This week, we’re highlighting three stocks to buy that have been dragged down by the current market turmoil.
These stocks are for great companies whose valuations are a little high. As valuations decline, investors should scoop up these quality businesses.
ICON PLC (ICLR) CEO Steven Cutler on Q4 2019 Results - Earnings Call Transcript
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.00% and -1.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ICON Public Limited Company (ICLR) CEO Steve Cutler on Q3 2019 Results - Earnings Call Transcript
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.58% and 0.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ERFSF vs. ICLR: Which Stock Is the Better Value Option?
Iconix Brand Group, Inc. (ICON) CEO Bob Galvin on Q2 2019 Results - Earnings Call Transcript
ERFSF vs. ICLR: Which Stock Is the Better Value Option?
ICON Public Limited Company (ICLR) CEO Steve Cutler on Q2 2019 Results - Earnings Call Transcript
Icon PLC (ICLR) delivered earnings and revenue surprises of 0.60% and 0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ICON Public Limited Company (ICLR) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
ICON plc (ICLR) CEO Steve Cutler on Q1 2019 Results - Earnings Call Transcript
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.88% and 0.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, stud... [Read more...]
| Industry Diagnostics & Research | IPO Date May 15, 1998 |
| CEO Stephen Cutler | Employees 16,000 |
| Stock Exchange NASDAQ | Ticker Symbol ICLR |
Financial Performance
In 2020, ICON plc's revenue was $2.80 billion, a decrease of -0.30% compared to the previous year's $2.81 billion. Earnings were $332.33 million, a decrease of -11.14%.
Analyst Forecasts
According to 16 analysts, the average rating for ICON plc stock is "Buy." The 12-month stock price forecast is 217.83, which is an increase of 20.56% from the latest price.